Aptose Biosciences and CrystalGenomics Announce Issuance of European Patent for CG-806

Aptose Biosciences (NASDAQ:APTO, TSX:APS), today announced that the European Patent Office has issued European Patent No. EP2940014B1 for CG-806, a first-in-class, highly potent oral small molecule being developed for acute myeloid leukemia (AML), B cell and other hematologic malignancies.

As quoted in the press release:

The granted patent claims various compounds, including the CG-806 compound, pharmaceutical compositions comprising the CG-806 compound, and uses for the treatment of various diseases, such as cancer. This European patent will be nationalized in, and cover, approximately forty European countries including the United Kingdom, France, Germany, Italy, Netherlands and Spain. The patent is expected to provide protection until the end of 2033.

“This is a meaningful decision by the EPO and adds to the previously issued patents in the US and Japan for CG-806,” stated Dr. William G. Rice, Chairman, President and Chief Executive Officer of Aptose.  “We will continue to strengthen the patent portfolio through additional findings and applications.”

Click here to read the full press release.